Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

N/A
1(33.3%)
Phase 1
1(33.3%)
Phase 2
1(33.3%)
3Total
N/A(1)
Phase 1(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07225036Not ApplicableRecruiting

Promoting Immunotherapy Efficacy With Low-Dose Liver RT

Role: lead

NCT03018418Phase 2Active Not Recruiting

Proton Therapy in Reducing Toxicity in Anal Cancer

Role: lead

NCT04480190Phase 1Withdrawn

Neoadjuvant Therapy in Biliary Adenocarcinoma

Role: lead

All 3 trials loaded